Frequency and genotype of human parvovirus B19 among Iranian patients infected with HIV

The human parvovirus B19 (B19) usually causes a subclinical infection in immunocompetent individuals. Whereas immunocompromised individuals such as patients infected with HIV are at risk of persistent anemia due to B19 infection. Only few studies have been carried out on distribution and molecular epidemiology of B19 in Iran. We aimed to determine the frequency and genotype of B19 among Iranian patients infected with HIV. We conducted a survey on 99 HIV patients and 64 healthy controls. IgG and IgM antibodies against B19 were detected by ELISA and B19 DNA was assessed by nested PCR. PCR products were subjected to direct sequencing and classified after phylogenetic analysis. The prevalence of B19 immunoglobulin was 11.1% for IgG and 1% for IgM. B19 DNA was detected in 13.1% of cases. The prevalence of B19 IgG, IgM, and DNA in control group was 25%, 1.6%, and 9.4%, respectively. B19 IgG was significantly lower in HIV group than in normal controls. There was no significant difference regarding anemia between cases and controls. All sequenced B19 isolates belonged to genotype 1A with low genetic diversity. Our findings indicated that in the HAART era, the importance of B19 infections in HIV patients may be limited whereas persistent B19 viremia in the circulation of healthy controls raises a potential concern in blood donations. J. Med. Virol. 87:1124–1129, 2015. © 2015 Wiley Periodicals, Inc.

[1]  S. A. de Oliveira,et al.  Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients , 2014, Memorias do Instituto Oswaldo Cruz.

[2]  Jiang Zhu,et al.  Human immunodeficiency virus/human parvovirus B19 co-infection in blood donors and AIDS patients in Sichuan, China. , 2012, Blood transfusion = Trasfusione del sangue.

[3]  L. Camacho,et al.  Parvovirus B19 seroconversion in a cohort of human immunodeficiency virus-infected patients. , 2012, Memorias do Instituto Oswaldo Cruz.

[4]  T. Williams,et al.  Parvovirus B19 infection and severe anaemia in Kenyan children: a retrospective case control study , 2010, BMC infectious diseases.

[5]  R. Weber,et al.  Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  O. Opare-Sem,et al.  Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa , 2009, Journal of medical virology.

[7]  S. Setúbal,et al.  Seroepidemiological study of human parvovirus B19 among human immunodeficiency virus-infected patients in a medium-sized city in Rio de Janeiro, Brazil. , 2009, Memorias do Instituto Oswaldo Cruz.

[8]  S. Başaran,et al.  Seroprevalence of parvovirus B19 in fibromyalgia syndrome , 2009, Clinical Rheumatology.

[9]  P. Kremsner,et al.  Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients. , 2006, The Journal of general virology.

[10]  J. Clewley,et al.  Genetic variants of parvovirus B19 identified in the United Kingdom: implications for diagnostic testing. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  E. Sabino,et al.  Sequence Variability of Human Erythroviruses Present in Bone Marrow of Brazilian Patients with Various Parvovirus B19-Related Hematological Symptoms , 2006, Journal of Clinical Microbiology.

[12]  F. Monteiro,et al.  Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors. , 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[13]  W. Fawzi,et al.  Anemia Is an Independent Predictor of Mortality and Immunologic Progression of Disease Among Women With HIV in Tanzania , 2005, Journal of acquired immune deficiency syndromes.

[14]  H. Neumayer,et al.  Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real‐time PCR for simultaneous detection of genotypes 1 to 3 , 2005, Journal of medical virology.

[15]  A. Parsyan,et al.  Identification and Characterization of Persistent Human Erythrovirus Infection in Blood Donor Samples , 2004, Journal of Virology.

[16]  Y. Cossart,et al.  Human Parvovirus B19 , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  S. Doyle,et al.  Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. , 2004, Journal of medical microbiology.

[18]  S. A. de Oliveira,et al.  Clinical presentation of parvovirus B19 infection in HIV-infected patients with and without AIDS. , 2003, Revista da Sociedade Brasileira de Medicina Tropical.

[19]  M. Söderlund-Venermo,et al.  A new parvovirus genotype persistent in human skin. , 2002, Virology.

[20]  Quang Tri Nguyen,et al.  Identification and characterization of a second novel human erythrovirus variant, A6. , 2002, Virology.

[21]  S. Laperche,et al.  Genetic Diversity within Human Erythroviruses: Identification of Three Genotypes , 2002, Journal of Virology.

[22]  D. Tyrrell,et al.  Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. , 2001, The Journal of general virology.

[23]  P. Koduri Parvovirus B19-related anemia in HIV-infected patients. , 2000, AIDS patient care and STDs.

[24]  J. Abkowitz,et al.  Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. , 1997, Journal of Infectious Diseases.

[25]  M. Salimans,et al.  Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  L. Anderson,et al.  Genetic diversity of human parvovirus B19: sequence analysis of the VP1/VP2 gene from multiple isolates. , 1996, The Journal of general virology.

[27]  H. Friedman,et al.  Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  J. Bremner,et al.  Parvovirus B19 as a cause of anemia in human immunodeficiency virus-infected patients. , 1994, The Journal of infectious diseases.

[29]  A. Alimenti,et al.  Secondary infection with parvovirus B19 in an HIV-positive patient. , 1993, AIDS.

[30]  J. Abkowitz,et al.  Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. , 1990, Annals of internal medicine.

[31]  N. Young,et al.  Persistent parvovirus B19 infections in humans. , 1989, Microbial pathogenesis.

[32]  P. Kluin,et al.  PROLONGED PARVOVIRUS B19 INFECTION WITH SEVERE ANAEMIA IN A BONE MARROW TRANSPLANT RECIPIENT , 1989, British journal of haematology.

[33]  A. Berrebi,et al.  TUMOUR NECROSIS FACTOR IN B CHRONIC LYMPHOCYTIC LEUKAEMIA , 1989, British journal of haematology.

[34]  D. Tyrrell,et al.  Circulating tumour necrosis factor-α and interferon-γ are detectable during acute and convalescent parvovirus B 19 infection and are associated with prolonged and chronic fatigue , 2022 .